Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 3724

Drug Profile

MT 3724

Alternative Names: MT3724

Latest Information Update: 13 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Molecular Templates; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Dec 2019 Efficacy and safety data from a phase I/Ib trial in Large B-cell lymphoma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 26 Apr 2019 Molecular Templates has patent protection for MT 3724
  • 08 Apr 2019 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03645395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top